Oncotarget

Case Reports:

Acquired-resistance of bevacizumab treatment for radiation brain necrosis: a case report

Hongqing Zhuang _, Xiangkun Yuan, Dayong Sun, Jianliang Bian, Joe Y. Chang, Zhiyong Yuan and Ping Wang

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:13265-13268. https://doi.org/10.18632/oncotarget.7724

Metrics: PDF 1470 views  |   HTML 1821 views  |   ?  


Abstract

Hongqing Zhuang1,*, Xiangkun Yuan2,*, Dayong Sun3, Jianliang Bian4, Joe Y. Chang5, Zhiyong Yuan1 and Ping Wang1

1 Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

2 Department of Radiotherapy, Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Hebei, China

3 Department of Chemo-Radiotherapy, Chengde Center Hospital, Second Clinical Medical School of Chengde Medical University, Hebei, China

4 Department of Radiotherapy, Affiliated Hospital of Hebei University, Hebei, China

5 Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

* These authors have contributed equally to this work

Correspondence to:

Hongqing Zhuang, email:

Dayong Sun, email:

Jianliang Bian, email:

Keywords: bevacizumab, acquired resistance, radiation brain necrosis

Received: September 14, 2015 Accepted: January 29, 2016 Published: February 25, 2016

Abstract

The case study reported on acquired bevacizumab resistance in one patient receiving re-treatment with bevacizumab following radiation brain necrosis progression after bevacizumab was discontinued. This case offers novel and additional insight for bevacizumab treatment. Low-dose bevacizumab is effective for radiation brain necrosis, and radiation brain necrosis may progress after bevacizumab discontinuation, whereas too many cycles of bevacizumab treatment may induce drug-resistance and re-treatment failure following the progression. Therefore, more rational administration for radiation brain necrosis with bevacizumab may include three aspects: short-course treatment, timely discontinuation upon obtaining satisfactory effects (to prevent long-term medication associated resistance) and re-treatment after brain necrosis progression.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7724